{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3251,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":3251,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"a541b9b1b08a","filters":{"topic":"Lymphoma Diagnosis and Treatment"}},"results":[{"id":"W2133201432","doi":"10.1200/jco.2006.09.2403","title":"Revised Response Criteria for Malignant Lymphoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4448,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Medical physics; Harmonization; Lymphoma; Positron emission tomography; Clinical trial; Oncology; Internal medicine; Nuclear medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1830828747671805,"gpt":0.5290861835862772,"spread":0.3460033088190968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01422156,0.000121136,0.001322309,0.0001239804,0.00004633707,0.000008371117,0.0001044544,0.0003245791,0.0001249238],"category_scores_gemma":[0.010908,0.00007619528,0.0007779118,0.00008556961,0.000115234,0.00005624002,0.00002425593,0.0001578716,0.00002436581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003209345,"about_ca_system_score_gemma":0.001521919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004266474,"about_ca_topic_score_gemma":0.000004433834,"domain_scores_codex":[0.9964332,0.0004222936,0.002462778,0.0001623648,0.0002463851,0.0002729631],"domain_scores_gemma":[0.9879258,0.009604478,0.001248628,0.0001947478,0.0005356601,0.000490648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1547112,0.007330968,0.06245675,0.00005386599,0.0007026815,0.005704816,0.0001010554,3.56788e-7,0.001799817,0.0005829858,0.04771424,0.7188413],"study_design_scores_gemma":[0.02086576,0.01982033,0.5403985,0.000120025,0.0003898151,0.000917596,0.00005556319,0.000009048169,0.001053335,0.0002555153,0.4160561,0.0000584194],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807442,0.0007096702,0.0005589846,0.01404681,0.00166259,0.0003378939,0.000004813805,0.000009040019,0.001925963],"genre_scores_gemma":[0.9757976,0.0003553906,0.01582222,0.005799468,0.001705279,0.00000663612,0.000001976228,0.00001590067,0.0004955137],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7187829,"threshold_uncertainty_score":0.9974235,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158267770","doi":"10.1182/blood-2003-05-1545","title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4277,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; U.S. Department of Health and Human Services","keywords":"Tissue microarray; Microarray; Lymphoma; Germinal center; Immunohistochemistry; Diffuse large B-cell lymphoma; Pathology; Biology; International Prognostic Index; Gene expression profiling; Microarray analysis techniques; Complementary DNA; Gene expression; Medicine; B cell; Antibody; Gene; Immunology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.008936389457920729,"gpt":0.2488582292168945,"spread":0.2399218397589738,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000637977,0.00008989214,0.0001678587,0.00001871935,0.00003407056,0.000003901908,0.00005512738,0.0000684656,0.00002000117],"category_scores_gemma":[0.00003412242,0.00006674174,0.00007560482,0.00009717777,0.00004364426,0.00001780672,0.00001066064,0.00002177576,0.00000237268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005947861,"about_ca_system_score_gemma":0.00009659185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004187055,"about_ca_topic_score_gemma":2.558017e-7,"domain_scores_codex":[0.9993585,0.00003640391,0.0002337684,0.0001176163,0.0001524145,0.0001012573],"domain_scores_gemma":[0.9993389,0.00001728395,0.0001995195,0.0003388166,0.00007370424,0.00003174373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00001227026,0.007437288,0.006104975,0.00009863589,0.00006194841,0.000002740751,0.0001226342,2.032639e-7,0.98569,0.000249277,0.00008968925,0.0001303299],"study_design_scores_gemma":[0.01207526,0.00004854664,0.005618493,0.00007312521,0.0003372439,0.00003267324,0.00008458525,0.00001596183,0.9804899,0.000009114753,0.001160668,0.00005449169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948158,0.002545912,0.0001318389,0.00004474416,0.00002974929,0.0002525502,0.00002583203,0.000007016847,0.002146555],"genre_scores_gemma":[0.9993285,0.00002691486,0.0004321732,0.00004051315,0.000005125963,0.00001426159,0.00002846274,0.00001064066,0.0001133843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01206299,"threshold_uncertainty_score":0.2721649,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2797584152","doi":"10.1056/nejmoa1801445","title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2261,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Frederick National Laboratory for Cancer Research; Leidos; Medical Research Council; Center for Strategic Scientific Initiatives, National Cancer Institute","keywords":"Biology; Germinal center; Diffuse large B-cell lymphoma; Lymphoma; Cell of origin; Gene expression profiling; Genetics; Gene; Pathogenesis; B cell; Cancer research; Gene expression; Immunology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.01415320434594938,"gpt":0.2627955426369702,"spread":0.2486423382910209,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000378804,0.0001363738,0.0005153074,0.0001461642,0.00003535202,0.000003779112,0.00006346521,0.00005972239,0.0001111279],"category_scores_gemma":[0.0001257368,0.00007959376,0.0000668936,0.0001126793,0.0001381958,0.00002970695,0.00002520521,0.0000470395,0.000003462026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003802307,"about_ca_system_score_gemma":0.0001515055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000381289,"about_ca_topic_score_gemma":0.00001474534,"domain_scores_codex":[0.9988337,0.00004298585,0.000474072,0.0001093995,0.0003716067,0.0001683073],"domain_scores_gemma":[0.9987801,0.0001367025,0.000300796,0.0001706797,0.0002610572,0.0003506418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00168494,0.004144986,0.352051,0.0001641619,0.0003700938,0.0008913,0.003021687,2.686421e-7,0.03040527,0.0001645959,0.01106411,0.5960376],"study_design_scores_gemma":[0.3949286,0.01071598,0.4595325,0.0006862716,0.001261826,0.002941185,0.0003217668,0.00005150388,0.0270963,0.0002403016,0.1020864,0.0001373333],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98636,0.009949101,0.0001302051,0.001974719,0.000298224,0.00009337292,0.000005258814,0.000004746933,0.001184395],"genre_scores_gemma":[0.9914747,0.004005337,0.001076714,0.0005006329,0.00267448,6.360443e-7,0.000002797359,0.00001412454,0.0002505379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5959002,"threshold_uncertainty_score":0.3245739,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160305510","doi":"10.1016/s1470-2045(06)70664-7","title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2085,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Vincristine; International Prognostic Index; Chemotherapy; Clinical endpoint; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Prednisone; Surgery; Cyclophosphamide; Gastroenterology; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.01156893336735901,"gpt":0.2673967495049783,"spread":0.2558278161376193,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001154473,0.0005698652,0.002038391,0.0001250528,0.0002144192,0.00008894791,0.0005683306,0.0003204145,0.000227789],"category_scores_gemma":[0.00007045313,0.0002982483,0.0004264909,0.0002791883,0.0002474453,0.0001069456,0.00006523229,0.0002893104,0.00003821738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001518935,"about_ca_system_score_gemma":0.0003287251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001205254,"about_ca_topic_score_gemma":0.00120423,"domain_scores_codex":[0.9962612,0.0006201012,0.000927905,0.0006544058,0.0007110225,0.0008253797],"domain_scores_gemma":[0.9970536,0.001397897,0.0006121207,0.0006840708,0.0001370823,0.0001152068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9362409,0.03976098,0.009694339,0.00001200509,0.001043807,0.00004185366,0.0005354779,0.000002468391,0.00006257374,0.0001356507,0.00851318,0.003956763],"study_design_scores_gemma":[0.9374016,0.005543079,0.01582389,0.00003368944,0.0004548167,0.00001478503,0.00008266584,0.0002257029,0.000108988,0.00004399001,0.03997402,0.0002928057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734367,0.0005853328,0.00003927503,0.006485387,0.002389621,0.01119837,0.00008594783,0.0001003844,0.005678972],"genre_scores_gemma":[0.9877065,0.0006240792,0.0001726956,0.003375192,0.002035218,0.004848215,0.0003129202,0.0000879435,0.0008372306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0342179,"threshold_uncertainty_score":0.999947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037796411","doi":"10.1056/nejmoa0802885","title":"Stromal Gene Signatures in Large-B-Cell Lymphomas","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1818,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Allos Therapeutics; National Cancer Institute; National Institutes of Health; Genentech; Celgene; Biogen; Amgen","keywords":"Vincristine; Medicine; Rituximab; CHOP; Prednisone; Lymphoma; Cyclophosphamide; Doxorubicin; Chemotherapy; Diffuse large B-cell lymphoma; Cancer research; B cell; Oncology; Stromal cell; Internal medicine; Immunology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.01635634650571655,"gpt":0.2560204910338821,"spread":0.2396641445281655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004110801,0.0001801768,0.0006209668,0.0002882998,0.00004491219,0.00000339627,0.00009527517,0.00009075756,0.0004442104],"category_scores_gemma":[0.0001593173,0.0001080905,0.0001087063,0.0001970849,0.00006474204,0.0000687205,0.00001707162,0.0002316473,0.0000080997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001615521,"about_ca_system_score_gemma":0.0003942726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001271262,"about_ca_topic_score_gemma":0.00003026745,"domain_scores_codex":[0.9983985,0.000058875,0.0005648865,0.0001407073,0.0005607453,0.0002762495],"domain_scores_gemma":[0.9989238,0.0001691604,0.0002312292,0.0001616391,0.000120043,0.0003940695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003349971,0.00329701,0.833666,0.00007762887,0.0003144703,0.03576109,0.003698953,0.0001305635,0.01165641,0.0002496334,0.0700939,0.03770433],"study_design_scores_gemma":[0.3348604,0.004978085,0.5819152,0.0005178191,0.000307128,0.009767991,0.0002009907,0.00005901263,0.009179392,0.0001515125,0.05789402,0.000168469],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789211,0.01193965,0.00005841429,0.004105575,0.000411121,0.0001303043,0.000002691248,0.00001019453,0.004421005],"genre_scores_gemma":[0.9921398,0.00218516,0.0009040578,0.0008933025,0.002905336,0.000001562651,0.000007383001,0.00001653822,0.0009468771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3315104,"threshold_uncertainty_score":0.4863792,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2744261860","doi":"10.1182/blood-2017-03-769620","title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1683,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Diffuse large B-cell lymphoma; Medicine; Ibrutinib; Lymphoma; Refractory (planetary science); Internal medicine; Leukemia; Chronic lymphocytic leukemia; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02363812012859347,"gpt":0.2921175936723523,"spread":0.2684794735437589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003067089,0.0001418991,0.0002372213,0.00003740816,0.0002344955,0.0001371561,0.0003783231,0.00005610424,0.00002846149],"category_scores_gemma":[0.0006517547,0.0000831015,0.00008542073,0.0000230231,0.00002613682,0.0001351806,0.0002011283,0.0001051506,0.0001239879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009156326,"about_ca_system_score_gemma":0.00006757418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001740035,"about_ca_topic_score_gemma":0.0008718834,"domain_scores_codex":[0.9988647,0.00004591507,0.0002647567,0.0003059962,0.0003408814,0.000177787],"domain_scores_gemma":[0.9985175,0.0002248691,0.0001557053,0.0009905087,0.00004201468,0.00006936135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001544576,0.06634201,0.9301407,0.000001351583,0.0002475134,0.0004566382,0.0008584035,2.097412e-8,0.00007780234,0.00001469564,0.0005724927,0.001133934],"study_design_scores_gemma":[0.1228621,0.0001648143,0.8690551,0.00003217694,0.000176341,0.000003357996,0.0004391973,0.000003234439,0.000749285,0.00001846616,0.006422412,0.00007351246],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907908,0.000216774,1.177741e-7,0.002390309,0.0003144291,0.0004086529,0.0001906118,0.00002505733,0.005663291],"genre_scores_gemma":[0.9982092,0.00007695473,0.00006486574,0.00046309,0.000172733,0.00005707561,0.00005796479,0.00001422357,0.0008839205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1227076,"threshold_uncertainty_score":0.3388781,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1979816280","doi":"10.1038/nature08638","title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","year":2010,"lang":"en","type":"article","venue":"Nature","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1645,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"U.S. Public Health Service; National Institutes of Health; Howard Hughes Medical Institute","keywords":"breakpoint cluster region; B-cell receptor; Lymphoma; B cell; Biology; Diffuse large B-cell lymphoma; Cancer research; PAX5; Receptor; Antibody; Immunology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.004481336229919334,"gpt":0.2448041591636851,"spread":0.2403228229337658,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009385201,0.000224766,0.0002979487,0.0001200802,0.00006580332,0.00002197219,0.000115326,0.001163075,0.0003875656],"category_scores_gemma":[0.00004054455,0.0001734467,0.0001371954,0.0002131282,0.00002728248,0.0000794306,0.00004646062,0.001213989,0.0002718141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000399433,"about_ca_system_score_gemma":0.0002558511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004265962,"about_ca_topic_score_gemma":0.0002115846,"domain_scores_codex":[0.998751,0.00002262522,0.0001768377,0.0003649684,0.0002808302,0.0004036931],"domain_scores_gemma":[0.9992996,0.0001007902,0.00007153573,0.0002957223,0.00006454145,0.0001677547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008603408,0.06655945,0.08877922,0.000496852,0.0002840834,0.001263381,0.002169885,0.000003791914,0.7371773,0.001775976,0.02418377,0.07644596],"study_design_scores_gemma":[0.07457161,0.0004797851,0.06643728,0.0001713805,0.000149641,0.00003420904,0.0001726451,0.0002035056,0.6890548,0.00006408759,0.1682533,0.000407673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885125,0.002919927,0.000002356252,0.001024305,0.0005353902,0.0004131019,0.00004540137,0.00005910678,0.006487943],"genre_scores_gemma":[0.9966669,0.0001779103,0.0003173188,0.0008411976,0.0005814335,0.0000625415,0.0001040798,0.00003462959,0.001214007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1440696,"threshold_uncertainty_score":0.8970702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2116382435","doi":"10.1038/nature09671","title":"Oncogenically active MYD88 mutations in human lymphoma","year":2010,"lang":"en","type":"article","venue":"Nature","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1509,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Howard Hughes Medical Institute","keywords":"Cancer research; Diffuse large B-cell lymphoma; Biology; Lymphoma; Mutation; Mutant; Ibrutinib; Gene; Genetics; Leukemia; Immunology; Chronic lymphocytic leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.007723989715644191,"gpt":0.3081169940131739,"spread":0.3003930042975297,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004597573,0.00009737154,0.0001565081,0.00008090517,0.00005400511,0.00001115104,0.00005747459,0.0007247503,0.0002104351],"category_scores_gemma":[0.00009693311,0.00007476864,0.00007705162,0.00015633,0.00003784045,0.00004564672,0.00001861647,0.0006744213,0.00005314964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001227155,"about_ca_system_score_gemma":0.0001221163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007144573,"about_ca_topic_score_gemma":0.0006115373,"domain_scores_codex":[0.9993673,0.00001165702,0.0001192328,0.0001896061,0.0001661194,0.0001460791],"domain_scores_gemma":[0.9995356,0.00006195316,0.00003303986,0.0002103508,0.00006506799,0.00009396092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004410536,0.008411017,0.4675653,0.00006396111,0.0004904612,0.00233858,0.002022581,0.0000027662,0.1694663,0.03575915,0.01486697,0.2985719],"study_design_scores_gemma":[0.003924206,0.0001255638,0.9449226,0.0000290875,0.00006407209,0.0000764453,0.00005298254,0.000008153305,0.02991374,0.0006346145,0.02016205,0.00008643067],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788386,0.0001356126,4.205786e-7,0.002638855,0.0001893672,0.0002297056,0.00001520954,0.00003591668,0.01791632],"genre_scores_gemma":[0.9973901,0.000008024729,0.0005174588,0.001336379,0.0001504043,0.00004779827,0.0000819066,0.00001177049,0.0004561433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4773573,"threshold_uncertainty_score":0.5589938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281625438","doi":"10.1182/blood.2022015851","title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1506,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Barts Charity","keywords":"Terminology; Medicine; Consensus conference; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03787384926230386,"gpt":0.3097163152171086,"spread":0.2718424659548048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004865682,0.00008067619,0.000163475,0.00001454295,0.0002056719,0.00001609179,0.0001982564,0.00004257935,0.0001254703],"category_scores_gemma":[0.0003198979,0.00004411016,0.0001495175,0.00007283928,0.0001162942,0.000008774732,0.0001203048,0.0001427574,0.00001147844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006282339,"about_ca_system_score_gemma":0.0002515895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001600135,"about_ca_topic_score_gemma":0.00004158377,"domain_scores_codex":[0.9987471,0.0001303232,0.0004421518,0.0001934972,0.0003930575,0.00009387946],"domain_scores_gemma":[0.9978274,0.00124273,0.0002776688,0.0005310866,0.00008039657,0.00004071194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002672517,0.002011029,0.9039674,0.000002843278,0.0005976477,0.0002939389,0.0001751795,0.000001478034,0.0004356326,0.0007718832,0.08438229,0.007093381],"study_design_scores_gemma":[0.004744277,0.000151692,0.7878614,0.0000176044,0.000373834,0.0009014523,0.0009329633,0.00008238467,0.0006302422,0.0002688063,0.2039843,0.00005104071],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694252,0.001245359,0.000001919553,0.02419016,0.0006501554,0.0002955876,0.0001188888,0.0000241416,0.004048593],"genre_scores_gemma":[0.9976233,0.0001586142,0.0002603862,0.0008760148,0.0002221412,0.0001217282,0.0001864452,0.000009836552,0.0005415467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.119602,"threshold_uncertainty_score":0.179876,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2072351874","doi":"10.1182/blood-2006-08-038257","title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1484,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"International Prognostic Index; Diffuse large B-cell lymphoma; Internal medicine; Rituximab; Medicine; CHOP; Oncology; Lymphoma; Progression-free survival; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.005419418758643413,"gpt":0.216134648355561,"spread":0.2107152295969176,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008734888,0.0002253541,0.0003010367,0.00004708639,0.0001416434,0.00004731819,0.0001540652,0.00005630714,0.00001785756],"category_scores_gemma":[0.00003290474,0.00009299769,0.0001159779,0.0001232819,0.00009109361,0.00005140341,0.00003355066,0.00004398543,0.000003115482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008189346,"about_ca_system_score_gemma":0.00007796001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006890323,"about_ca_topic_score_gemma":0.00005014957,"domain_scores_codex":[0.9985465,0.00003060129,0.0003364886,0.0002590583,0.0005473513,0.0002799982],"domain_scores_gemma":[0.9988038,0.0002428906,0.000225103,0.0003721581,0.0002918573,0.0000641852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001495744,0.01002904,0.9864951,0.00005479325,0.0005180374,0.00001468671,0.00009783753,2.215641e-7,0.000006183735,0.00004346119,0.0007307156,0.0005141198],"study_design_scores_gemma":[0.08694106,0.001713722,0.9042866,0.0001587245,0.0008694925,0.000007117479,0.00003060717,0.00002794911,0.001175339,0.00001524948,0.004665524,0.0001086655],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958372,0.0001720599,0.00003431138,0.0009828304,0.00004558382,0.001875942,0.0006307796,0.00003453297,0.0003867334],"genre_scores_gemma":[0.9983429,0.00002121199,0.0001580704,0.0002876516,0.0001100855,0.0004675754,0.0001783978,0.00003652159,0.0003976294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08544531,"threshold_uncertainty_score":0.3792336,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2034400622","doi":"10.1056/nejmoa0905680","title":"Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1260,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medicine; Lymphoma; Oncology; Hodgkin lymphoma; Disease; Internal medicine; Classical Hodgkin lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.01196114929335412,"gpt":0.2660067477339572,"spread":0.2540455984406031,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008399863,0.0001757606,0.0006616262,0.0002427494,0.00003526503,0.00001221494,0.00007580769,0.00008242149,0.0001934094],"category_scores_gemma":[0.0007138252,0.000106408,0.00006266117,0.0001916797,0.0001265653,0.00007019567,0.00002067224,0.0002731295,0.0000037722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009361705,"about_ca_system_score_gemma":0.0002429879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003413865,"about_ca_topic_score_gemma":0.00049832,"domain_scores_codex":[0.9985992,0.00007465178,0.0005049647,0.0001453138,0.0004446218,0.0002313043],"domain_scores_gemma":[0.9986998,0.0003552722,0.0002763456,0.0001382179,0.0001293283,0.0004010568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007364578,0.0005429914,0.6742753,0.00002759947,0.0001859211,0.004738629,0.0006706211,9.805104e-7,0.00606269,0.0002546608,0.003204264,0.3092998],"study_design_scores_gemma":[0.1129053,0.001786298,0.8664008,0.0003936489,0.0002248804,0.00302288,0.000135818,0.00002460351,0.0007363805,0.0003934538,0.01388513,0.00009084498],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859823,0.001661172,0.000005824143,0.009701917,0.0009469814,0.0001119182,0.000002079443,0.00001061428,0.001577212],"genre_scores_gemma":[0.9965096,0.0005760248,0.0002475634,0.0005377857,0.001836332,0.000001528427,0.000004369867,0.00001644883,0.000270365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.309209,"threshold_uncertainty_score":0.4339191,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2050115670","doi":"10.1016/s0140-6736(16)32407-2","title":"Non-Hodgkin lymphoma","year":2017,"lang":"en","type":"review","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1176,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Hodgkin lymphoma; Medicine; Non-Hodgkin's lymphoma; Oncology; Immunology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1675278764050077,"gpt":0.4133069042580451,"spread":0.2457790278530374,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002212981,0.0003126704,0.002560053,0.00004031283,0.0001542018,0.00007050265,0.0004905289,0.0001686439,0.0001025915],"category_scores_gemma":[0.00004840563,0.0001426805,0.0005131926,0.00005346566,0.00007712172,0.00002148762,0.0001111082,0.0001075297,0.001526062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001874793,"about_ca_system_score_gemma":0.0003102078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006179411,"about_ca_topic_score_gemma":0.000005409268,"domain_scores_codex":[0.9989315,0.00004285374,0.0002601233,0.0002672918,0.0001922738,0.0003059788],"domain_scores_gemma":[0.9975679,0.0001075421,0.0002719751,0.001946444,0.0000230737,0.00008308864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001095971,0.00009186152,0.00009644385,0.003568397,0.0003772507,0.0001586987,0.00001704074,4.408027e-9,9.774808e-9,0.000138923,0.07457384,0.9209666],"study_design_scores_gemma":[0.001540165,0.00007420237,0.001366015,0.01201403,0.001982658,0.0002931359,0.000001567274,6.550533e-7,8.62376e-7,0.0000312497,0.9825534,0.000142061],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000137843,0.9537025,3.904194e-7,0.0008109305,0.0003178739,0.0007701311,0.00005762446,0.0000449479,0.04428181],"genre_scores_gemma":[0.00006451831,0.9923191,0.00006506577,0.0003888122,0.002801051,0.0002797326,0.0001109885,0.00004233345,0.003928395],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9208245,"threshold_uncertainty_score":0.9992514,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016044607","doi":"10.1016/j.ccell.2020.03.015","title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","year":2020,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University","funders":"National Cancer Institute; National Institutes of Health; Terry Fox Research Institute; AbbVie; Genentech; Celgene; Janssen Biotech; Roche","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Computational biology; Cancer research; Probabilistic logic; Biology; Computer science; Immunology; Artificial intelligence","retraction":null,"screen_n_in":null,"score":{"opus":0.03299643181904677,"gpt":0.2739337415544668,"spread":0.24093730973542,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002220959,0.000122324,0.0002074125,0.00001504907,0.00004587957,0.000009397127,0.00006611831,0.0000441728,0.00005215893],"category_scores_gemma":[0.00000748093,0.00008793116,0.00007044608,0.0001147216,0.000035729,0.00002692904,0.00001010037,0.00001754917,0.000009416146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001760217,"about_ca_system_score_gemma":0.0002714768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003837,"about_ca_topic_score_gemma":0.00002706957,"domain_scores_codex":[0.9992721,0.00001244343,0.0001873168,0.0002632181,0.00009730658,0.0001675774],"domain_scores_gemma":[0.9993384,0.00006523821,0.0001131524,0.0002607739,0.0001279765,0.00009444803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002290266,0.02246295,0.7718288,0.004502185,0.0005623309,0.00001377795,0.00435506,0.00008536472,0.109777,0.004985694,0.004830789,0.07430568],"study_design_scores_gemma":[0.02084067,0.001373616,0.9027336,0.00007103371,0.001029514,0.000004462576,0.0001933299,0.001994059,0.0549642,0.0001469507,0.01641533,0.0002332698],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903938,0.003619757,0.001365715,0.00203596,0.00003075983,0.001508884,0.0001559535,0.00003976296,0.0008493642],"genre_scores_gemma":[0.9963353,0.000409429,0.001018921,0.0007950256,0.00007260799,0.001136958,0.00005150464,0.00002578254,0.000154533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1309047,"threshold_uncertainty_score":0.3585728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111500154","doi":"10.1084/jem.20031074","title":"Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma","year":2003,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1101,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Lymphoma; Diffuse large B-cell lymphoma; Pathology; Gene expression profiling; Cancer research; Biology; B cell; Medicine; Gene; Immunology; Gene expression; Antibody; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01464565170772613,"gpt":0.2828617615987876,"spread":0.2682161098910614,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00205611,0.0005445073,0.001806826,0.0004368787,0.0001272604,0.00001410221,0.0005270763,0.0002100386,0.000341347],"category_scores_gemma":[0.0006022076,0.0003424102,0.0005163912,0.0006990786,0.0004897655,0.000166536,0.0001692489,0.000137331,0.00002507181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006046115,"about_ca_system_score_gemma":0.0005191726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001685304,"about_ca_topic_score_gemma":0.000003286338,"domain_scores_codex":[0.9942001,0.0005528476,0.002638376,0.0003803342,0.001613189,0.000615226],"domain_scores_gemma":[0.9952677,0.001119755,0.001716335,0.0007892423,0.0004643195,0.0006426076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006636218,0.07487344,0.07144474,0.000580303,0.001386371,0.002199339,0.01473333,0.00002242888,0.8137569,0.0005276878,0.008104649,0.005734614],"study_design_scores_gemma":[0.06579069,0.009910859,0.03163096,0.001397224,0.001230621,0.0009741785,0.005777312,0.0000147828,0.8818411,0.0001059059,0.00103245,0.00029397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716173,0.02171748,0.00006757567,0.0007279904,0.0007003494,0.0007681458,0.00002257527,0.00002066495,0.004357861],"genre_scores_gemma":[0.995515,0.002083455,0.0008380745,0.001070922,0.0001226792,0.00004782186,0.00001696647,0.00007825682,0.0002267533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06808418,"threshold_uncertainty_score":0.9999028,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.05924066866749524,"gpt":0.4100624161401102,"spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00319185,0.0002270051,0.002129924,0.0002478317,0.00004543801,0.000004300372,0.0001545336,0.0003048943,0.00004138225],"category_scores_gemma":[0.002811887,0.0001268417,0.0002705371,0.0002617084,0.00009434174,0.0001691343,0.00007828018,0.0003895775,0.00001393253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000583372,"about_ca_system_score_gemma":0.001583723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003538698,"about_ca_topic_score_gemma":0.00008038376,"domain_scores_codex":[0.9943848,0.0007306376,0.003597907,0.0002449625,0.0006275878,0.0004141675],"domain_scores_gemma":[0.9929075,0.002702887,0.003145382,0.0003277029,0.0004262275,0.0004902562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08750263,0.269597,0.6161203,0.00005500649,0.0004323373,0.0006992387,0.0006238963,0.000002412259,0.000007249552,0.000002669077,0.001331133,0.02362612],"study_design_scores_gemma":[0.2913716,0.1708482,0.5330142,0.000354415,0.0007104037,0.00008739443,0.0004292887,0.0000112691,0.00001855691,9.616061e-7,0.00306997,0.00008373948],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971379,0.0005109746,0.000004516281,0.0001884553,0.00100257,0.0006911681,0.00002715024,0.000007393602,0.0004298814],"genre_scores_gemma":[0.9987565,0.0001331538,0.0003499395,0.0002062886,0.0003666779,0.00001301524,0.00000985361,0.00002372428,0.000140879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2038689,"threshold_uncertainty_score":0.5172456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145304413","doi":"10.1200/jco.2005.09.137","title":"Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; International Prognostic Index; Internal medicine; Vincristine; Diffuse large B-cell lymphoma; Prednisone; CHOP; Population; Cyclophosphamide; Lymphoma; Gastroenterology; Oncology; Surgery; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.04227816456457361,"gpt":0.3824355696899724,"spread":0.3401574051253988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00222366,0.0001231208,0.002393829,0.00009560715,0.00002374093,0.00001708856,0.0001604817,0.0003865047,0.0003098228],"category_scores_gemma":[0.001804552,0.000122907,0.0005880951,0.0001661503,0.0001893935,0.000115874,0.00004495206,0.0003204963,0.000008702478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004299795,"about_ca_system_score_gemma":0.000912395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009784792,"about_ca_topic_score_gemma":0.004751514,"domain_scores_codex":[0.9949046,0.000324567,0.00394853,0.0002094849,0.0003516822,0.0002610799],"domain_scores_gemma":[0.9957454,0.001114088,0.002159519,0.0002600173,0.000476225,0.0002448081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00457474,0.1387004,0.5861784,0.00009498622,0.0004222497,0.0003203165,0.0001292943,0.000003342743,0.0005268418,0.00003921452,0.005561392,0.2634489],"study_design_scores_gemma":[0.2072172,0.01338505,0.7592835,0.00008078486,0.0002258373,0.0002087084,0.00008532662,0.0003182514,0.00028166,0.00009412729,0.0187293,0.00009022317],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991711,0.0005832715,0.00002513032,0.0063382,0.0005809601,0.0003750752,0.00001040975,0.000006846654,0.0003690774],"genre_scores_gemma":[0.9926847,0.001569291,0.003343838,0.001106162,0.0008824282,0.000009096997,0.000005540078,0.00001814962,0.0003807997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2633587,"threshold_uncertainty_score":0.5012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2030105242","doi":"10.1073/pnas.0804295105","title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","year":2008,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":985,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Diffuse large B-cell lymphoma; Biology; Cancer research; Germinal center; Gene expression profiling; Amplicon; Lymphoma; Gene knockdown; Genetics; B cell; Gene; Gene expression; Immunology; Polymerase chain reaction","retraction":null,"screen_n_in":null,"score":{"opus":0.02456028697359717,"gpt":0.2602217104356238,"spread":0.2356614234620266,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002619129,0.0001035437,0.0002186443,0.00009052089,0.0001197468,0.000004984368,0.0003022015,0.00006511145,0.000009284764],"category_scores_gemma":[0.0001902166,0.00006366299,0.0001164134,0.0003961935,0.0005673976,0.00009406839,0.00008370725,0.00004104438,0.000001703077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004715639,"about_ca_system_score_gemma":0.00006975145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001201801,"about_ca_topic_score_gemma":2.829236e-8,"domain_scores_codex":[0.9982839,0.000004346079,0.0003073053,0.000209755,0.001042672,0.0001519747],"domain_scores_gemma":[0.9993124,0.00006797694,0.0003400629,0.00001280882,0.0002106063,0.00005613609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00006889337,0.005237425,0.528385,0.0002131789,0.00006506614,4.978191e-7,0.0004123977,0.000004762215,0.4524725,0.01011053,0.002421819,0.000607967],"study_design_scores_gemma":[0.001877452,0.0001197498,0.416823,0.00005820644,0.00003764193,0.00002312625,0.00004953676,0.0001447448,0.5788089,0.001864016,0.0001437351,0.00004986145],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935624,0.001015542,7.453021e-7,0.0006309924,0.000008729069,0.0001852758,0.00004831648,0.000007765812,0.004540239],"genre_scores_gemma":[0.998979,0.0001719705,0.0005496879,0.0001844559,0.000020727,0.00001331116,6.019828e-7,0.000004910374,0.00007537072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1263364,"threshold_uncertainty_score":0.2596101,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159862107","doi":"10.1200/jco.2011.41.0985","title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":973,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Vincristine; Medicine; Chromosomal translocation; International Prognostic Index; Immunohistochemistry; Rituximab; Lymphoma; Cyclophosphamide; Prednisone; Diffuse large B-cell lymphoma; Cancer research; CHOP; Internal medicine; Oncology; Cohort; Immunophenotyping; Pathology; Chemotherapy; Immunology; Flow cytometry; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.04353290157636887,"gpt":0.3813756691600561,"spread":0.3378427675836872,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00113866,0.0002033415,0.001817267,0.0001242474,0.00003212312,0.000006342521,0.00006476943,0.0002911844,0.00002415892],"category_scores_gemma":[0.0005330514,0.0001197746,0.0001419042,0.0001130709,0.0002224452,0.000137757,0.0000766683,0.0002463694,0.000002316991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001969788,"about_ca_system_score_gemma":0.0004556659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005487232,"about_ca_topic_score_gemma":0.0000306391,"domain_scores_codex":[0.9972656,0.0002626405,0.001662331,0.0002001783,0.0002873566,0.0003218453],"domain_scores_gemma":[0.9964409,0.001427441,0.001260834,0.0001563187,0.0001885627,0.00052597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004259559,0.04265846,0.91596,0.0001051148,0.0001456937,0.0003727913,0.0002775052,4.252949e-7,0.0003346579,0.0000577551,0.0005701532,0.03525792],"study_design_scores_gemma":[0.1674097,0.01219377,0.8097914,0.0004038129,0.0004549568,0.0004354477,0.0001697082,0.00004047941,0.003333733,0.00001196459,0.005649601,0.0001054084],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886658,0.009759297,0.0000260028,0.0004639786,0.0002325973,0.0002844362,0.00001526327,0.000006347916,0.0005462398],"genre_scores_gemma":[0.9941347,0.004234363,0.001007127,0.0003142824,0.0002230341,0.000009576138,0.000005179845,0.00001695737,0.00005480508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1631501,"threshold_uncertainty_score":0.4884267,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2063691874","doi":"10.1182/blood-2013-09-524108","title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Rituximab; International Prognostic Index; Diffuse large B-cell lymphoma; Medicine; Internal medicine; Lymphoma; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.004760218311381972,"gpt":0.222502393562567,"spread":0.2177421752511851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005562737,0.0001774983,0.0002134416,0.00008112178,0.00005902942,0.00005942334,0.000143025,0.00006421132,0.00006262757],"category_scores_gemma":[0.00003647108,0.00009989575,0.00005671456,0.0001199107,0.00002480079,0.0001371225,0.00001701696,0.00004248361,0.00004361602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006695504,"about_ca_system_score_gemma":0.0000514143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001353753,"about_ca_topic_score_gemma":0.00007130669,"domain_scores_codex":[0.9989384,0.00003364592,0.0001994131,0.0002773173,0.0002768979,0.000274339],"domain_scores_gemma":[0.9992958,0.000110171,0.0000758344,0.0002784259,0.0001541813,0.00008560363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002027957,0.1089348,0.8869172,0.00002182275,0.0001155944,0.00002084883,0.0004107238,2.286857e-7,0.00008884571,0.00003287458,0.0001540758,0.003100191],"study_design_scores_gemma":[0.1278016,0.001473472,0.8670149,0.00006369475,0.0001832795,0.000007662848,0.00008586376,0.0001596589,0.002877341,0.0000261251,0.0001912525,0.0001151023],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967666,0.0000455903,0.00002924881,0.0002779389,0.00004683879,0.001960547,0.000057866,0.00003724509,0.0007781098],"genre_scores_gemma":[0.9971492,0.00001143373,0.0002936893,0.0004660735,0.00006916648,0.001472165,0.0004444522,0.00002402448,0.00006973897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1275988,"threshold_uncertainty_score":0.4073631,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2504623699","doi":"10.1016/s1470-2045(16)30167-x","title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"NIHR Oxford Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Medicine; Nivolumab; Internal medicine; Oncology; Autologous stem-cell transplantation; Clinical endpoint; Transplantation; Lymphoma; Surgery; Clinical trial; Hodgkin lymphoma; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03356002623975395,"gpt":0.3124283474722595,"spread":0.2788683212325055,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002367314,0.0002068337,0.0007761262,0.00005551912,0.00006140576,0.00001094953,0.0000976558,0.0001935058,0.00004757259],"category_scores_gemma":[0.00003692508,0.0001103048,0.0001429874,0.00005581271,0.0002401629,0.00005303292,0.0000251353,0.00005222616,0.00000939279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002595723,"about_ca_system_score_gemma":0.0001707116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003475613,"about_ca_topic_score_gemma":0.0001592311,"domain_scores_codex":[0.9985448,0.0001871704,0.0003930354,0.0003321338,0.0001581626,0.0003847735],"domain_scores_gemma":[0.9983104,0.001002184,0.0002161484,0.0002933206,0.00006645816,0.0001115224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.290303,0.01975297,0.007708684,0.0004487826,0.0004874701,0.0003921291,0.002147906,8.066588e-7,0.01316145,0.0003246843,0.002780241,0.6624919],"study_design_scores_gemma":[0.8808955,0.02496547,0.03018795,0.0002505837,0.002069913,0.0004007657,0.000223776,0.0004352398,0.0190137,0.0001079539,0.04115033,0.0002988215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903803,0.0004380848,0.0004548731,0.00613306,0.0002903796,0.0017667,0.0001961402,0.00004804447,0.0002924155],"genre_scores_gemma":[0.9966546,0.0003064448,0.001472069,0.0004089352,0.0004210561,0.0004643,0.00002805663,0.00002368606,0.0002208634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6621931,"threshold_uncertainty_score":0.4498097,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118028844","doi":"10.1038/nature11378","title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","year":2012,"lang":"en","type":"article","venue":"Nature","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":915,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Cancer Research UK","keywords":"Lymphoma; Cancer research; Biology; Oncogene; Cell cycle; Cancer; Genetics; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.01080872948758549,"gpt":0.2404201434775254,"spread":0.2296114139899399,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003533237,0.0001300407,0.0001600632,0.00002935638,0.00007667169,0.0000159916,0.00001706453,0.0004078118,0.0001111763],"category_scores_gemma":[0.000009944914,0.00009002578,0.00003755651,0.0000370258,0.00003654525,0.00004785544,0.00002666469,0.0001338448,0.000007460905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001085304,"about_ca_system_score_gemma":0.00003073965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002660366,"about_ca_topic_score_gemma":0.000004233106,"domain_scores_codex":[0.9994373,0.00001453943,0.00008042627,0.0001700951,0.0001288378,0.0001688292],"domain_scores_gemma":[0.9996266,0.00005578992,0.00002945886,0.0001156157,0.00002804355,0.0001444344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001531524,0.0001069546,0.8813733,0.00001519516,0.0002597214,0.00001937896,0.0003643949,2.67922e-7,0.006769486,0.0007485623,0.0007281977,0.1094613],"study_design_scores_gemma":[0.001895032,0.00004634662,0.9803698,0.000009175365,0.0001933438,0.0001157603,0.00004732391,0.0000374802,0.002491314,0.0002986576,0.01440311,0.00009262927],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9033561,0.09539083,0.000003629055,0.0006543241,0.0002909939,0.0001213614,0.00005769181,0.00002016064,0.0001049291],"genre_scores_gemma":[0.9964432,0.0004277463,0.0006004366,0.001841493,0.0004727523,0.00001082632,0.0001043137,0.00001391725,0.0000852872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1093687,"threshold_uncertainty_score":0.3671145,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1995314727","doi":"10.1056/nejmoa055759","title":"Molecular Diagnosis of Burkitt's Lymphoma","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":903,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Lymphoma; Burkitt's lymphoma; Medicine; Gene expression profiling; Diffuse large B-cell lymphoma; Pathology; BCL10; Cancer research; Gene expression; Gene; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.009913088923979619,"gpt":0.252875592312471,"spread":0.2429625033884913,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003530684,0.0001670081,0.0006882428,0.0002288823,0.00002178201,0.000004416758,0.00009403403,0.00006611896,0.0002375392],"category_scores_gemma":[0.0001995427,0.0001008826,0.000170468,0.0002033241,0.000100806,0.00005205533,0.0000149897,0.00007690406,0.000003711611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009953541,"about_ca_system_score_gemma":0.0002064765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006659238,"about_ca_topic_score_gemma":0.00002124009,"domain_scores_codex":[0.9983285,0.00004852585,0.0007055564,0.0001169588,0.0006174512,0.0001829727],"domain_scores_gemma":[0.9986514,0.0002208295,0.0004202887,0.0001973236,0.0002542411,0.0002559106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001131676,0.001564071,0.4752093,0.0001199926,0.00056767,0.004606028,0.000354153,0.00008283449,0.007389151,0.002091923,0.0632757,0.4436075],"study_design_scores_gemma":[0.2030527,0.006668052,0.4940372,0.001847601,0.001811452,0.005054355,0.0001265003,0.00002150379,0.09818413,0.002066178,0.1869261,0.000204229],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748797,0.00662815,0.0001254809,0.01334206,0.0003303627,0.0001291768,0.000002966234,0.000009052362,0.004553055],"genre_scores_gemma":[0.9953955,0.000923537,0.0005571204,0.0006889685,0.002229848,0.000003317886,0.000008717688,0.00001695366,0.0001760232],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4434033,"threshold_uncertainty_score":0.4113873,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145453495","doi":"10.1016/s1470-2045(11)70235-2","title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":811,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Rituximab; CHOP; Diffuse large B-cell lymphoma; Open label; Internal medicine; Oncology; Lymphoma; Chemotherapy; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.04605573310528138,"gpt":0.3159028828759636,"spread":0.2698471497706822,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008306747,0.0002373535,0.00104432,0.00007057602,0.00006801935,0.00001558879,0.0006748911,0.00009823235,0.00004335795],"category_scores_gemma":[0.00004346916,0.0001004807,0.00004255819,0.0002242018,0.0001549266,0.000102934,0.0001511203,0.0001143749,0.000002523537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002325536,"about_ca_system_score_gemma":0.0002195373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001819171,"about_ca_topic_score_gemma":0.006389767,"domain_scores_codex":[0.9979072,0.0004547939,0.0005654558,0.0003698625,0.0003923417,0.0003103589],"domain_scores_gemma":[0.9983307,0.0002066769,0.000562821,0.0006882984,0.0001496831,0.00006178943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4826254,0.1348473,0.3756017,0.00001282115,0.0003676744,0.00001717875,0.004942117,1.767262e-7,0.00002093508,0.00003625464,0.00006529802,0.001463138],"study_design_scores_gemma":[0.6499186,0.01794732,0.3305367,0.00006307852,0.0002092111,0.000007821829,0.00070759,0.00002498551,0.0002670601,0.000009676733,0.0002260081,0.00008201209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907629,0.00001478545,0.000002787927,0.0002553858,0.0002259202,0.005212453,0.00006258204,0.00001688848,0.003446293],"genre_scores_gemma":[0.9977812,0.00004337305,0.0008516579,0.0003170328,0.000107235,0.000681837,0.00002940526,0.00003561679,0.0001526251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1672931,"threshold_uncertainty_score":0.4097483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2761878534","doi":"10.1056/nejmoa1614598","title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":788,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Foothills Medical Centre","funders":"Cancer Research UK","keywords":"Obinutuzumab; Rituximab; Medicine; Follicular lymphoma; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Adverse effect; Lymphoma; CD20; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.04278529139120291,"gpt":0.3180883775896582,"spread":0.2753030861984553,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003609657,0.0001814091,0.0007151966,0.0000801463,0.0002168327,0.00001428416,0.0001900728,0.00005665961,0.00007687376],"category_scores_gemma":[0.0003851593,0.00007721076,0.0002825065,0.00003924566,0.0001539821,0.00005864074,0.00001534986,0.00003630057,0.000002025319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003038465,"about_ca_system_score_gemma":0.0003556133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005778165,"about_ca_topic_score_gemma":0.0001043995,"domain_scores_codex":[0.9987753,0.00001653015,0.000534349,0.000118177,0.0003766583,0.0001790012],"domain_scores_gemma":[0.9978428,0.0004790056,0.0006935156,0.0005179212,0.0002530381,0.0002137104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00325337,0.0007048129,0.03076808,0.00006730865,0.001519495,0.0004790231,0.001116509,0.0000428158,0.0003003115,0.0004205474,0.009734675,0.951593],"study_design_scores_gemma":[0.2641046,0.01699851,0.1344731,0.0006780894,0.002645508,0.001727581,0.0001165923,0.0001905909,0.005907061,0.0005700781,0.5724913,0.00009693876],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9020374,0.02006665,0.0007213542,0.07359252,0.0014156,0.0008948157,0.00001366261,0.000009613645,0.00124838],"genre_scores_gemma":[0.989033,0.005355293,0.0004073258,0.0003003803,0.00421994,0.00001399668,0.000005050637,0.00001618709,0.0006487964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9514961,"threshold_uncertainty_score":0.3148564,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2984927918","doi":"10.1200/jco.19.00172","title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":772,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada); Seagen (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Exelixis; Karyopharm Therapeutics; MEI Pharma; Astex Pharmaceuticals; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Kite Pharma; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bendamustine; Rituximab; Neutropenia; Hazard ratio; Cohort; Diffuse large B-cell lymphoma; Transplantation; Gastroenterology; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.06801833353446632,"gpt":0.4233675724693748,"spread":0.3553492389349084,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001771317,0.0001724098,0.001712863,0.0001894964,0.00002092021,0.000007734182,0.0001636982,0.0005401575,0.0004663332],"category_scores_gemma":[0.00191558,0.0001037566,0.0005308267,0.0001673091,0.00006186616,0.00008588007,0.00006375115,0.0005456982,0.0003472771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006938007,"about_ca_system_score_gemma":0.002775801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003192472,"about_ca_topic_score_gemma":0.00007299961,"domain_scores_codex":[0.9963262,0.0004022768,0.002335361,0.0002390859,0.0003661171,0.000330931],"domain_scores_gemma":[0.994682,0.003031228,0.001393656,0.0003100442,0.0001785994,0.0004045453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01840059,0.09399652,0.7667812,0.0000669388,0.0003347149,0.007812946,0.0002529161,0.000002027659,0.000243529,0.0001855405,0.008129993,0.1037931],"study_design_scores_gemma":[0.1362647,0.02074762,0.6246415,0.0001577057,0.0001967162,0.0003366221,0.0001754876,0.00006541247,0.0001013126,0.00006105538,0.2171507,0.0001011676],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854438,0.000961564,0.000002306253,0.00259892,0.001642978,0.0002529017,0.000003070495,0.000009594343,0.009084875],"genre_scores_gemma":[0.9916303,0.0011457,0.0008831769,0.00350506,0.0005739271,0.000004158208,0.000002981628,0.00002283489,0.002231885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2090207,"threshold_uncertainty_score":0.5106022,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2039888190","doi":"10.1056/nejmoa1408648","title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":750,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Thomas Hospital","funders":"Leukaemia and Lymphoma Research; Cancer Research UK; National Institute for Health and Care Research; Teenage Cancer Trust","keywords":"ABVD; Vinblastine; Dacarbazine; Bleomycin; Medicine; Positron emission tomography; Stage (stratigraphy); Lymphoma; Hodgkin lymphoma; Radiation therapy; Hodgkin's lymphoma; Chemotherapy; Oncology; Doxorubicin; Nuclear medicine; Internal medicine; Radiology; Vincristine; Cyclophosphamide","retraction":null,"screen_n_in":null,"score":{"opus":0.05951511092452814,"gpt":0.3269730988975245,"spread":0.2674579879729963,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001395085,0.0001721343,0.0009902137,0.000236339,0.00001668652,0.000003568943,0.0001136472,0.00006287603,0.00003094635],"category_scores_gemma":[0.001402472,0.00009683935,0.0001963845,0.0001823694,0.00008545676,0.00005614734,0.00001106343,0.00007225799,7.959616e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009705749,"about_ca_system_score_gemma":0.000676187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006169825,"about_ca_topic_score_gemma":0.00002146618,"domain_scores_codex":[0.9978248,0.00009669592,0.00106705,0.0001342397,0.0006985441,0.000178674],"domain_scores_gemma":[0.9971845,0.0004988299,0.0009390786,0.0002417472,0.0007374553,0.0003983752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6102227,0.002430976,0.00962643,0.00008846901,0.001083487,0.0005103934,0.004293341,0.000009104723,0.002318248,0.0001067688,0.04450162,0.3248084],"study_design_scores_gemma":[0.8693152,0.03849724,0.02124829,0.0005498725,0.0003854093,0.0004292522,0.0002614016,0.00002649923,0.007981619,0.0002063126,0.06102073,0.00007818184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901789,0.002075097,0.00005525867,0.004930137,0.0008043702,0.0006131185,0.00002678567,0.00001218249,0.001304081],"genre_scores_gemma":[0.9939747,0.001005226,0.00145429,0.0001478755,0.002680829,0.000006389194,0.00001633285,0.0000188751,0.0006954935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3247303,"threshold_uncertainty_score":0.3948994,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2903308035","doi":"10.1016/s0140-6736(18)32984-2","title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":726,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Brentuximab vedotin; Medicine; Chemotherapy; Oncology; Internal medicine; Lymphoma; Peripheral; CD30; Peripheral T-cell lymphoma; Double blind; Phases of clinical research; Immunology; Pathology; T cell; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03926279559710762,"gpt":0.3382484745491339,"spread":0.2989856789520263,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031169,0.0003051471,0.000809187,0.00002527605,0.0002139389,0.00008408137,0.0002172552,0.0000971373,0.0001348141],"category_scores_gemma":[0.00001799113,0.0001660398,0.0002240085,0.0001874686,0.0002211169,0.00006119481,0.00002577071,0.0000536051,0.00005052685],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002976214,"about_ca_system_score_gemma":0.0002761486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001289799,"about_ca_topic_score_gemma":0.00003949799,"domain_scores_codex":[0.998494,0.0000597914,0.0002838571,0.0003879428,0.0002841828,0.0004902201],"domain_scores_gemma":[0.9987943,0.0001416873,0.0001625074,0.0005990934,0.0001625333,0.0001399443],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9617366,0.004079477,0.0007176073,0.00003460337,0.0005272504,0.00002742319,0.0005788025,4.992754e-7,0.0002568914,0.0002304042,0.01374017,0.01807027],"study_design_scores_gemma":[0.9512554,0.007361802,0.0007246095,0.00009166828,0.0004681626,0.00007882345,0.00008708313,0.0001283065,0.01984214,0.00009541482,0.01965987,0.0002066912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779921,0.0004868248,0.0003893754,0.006732006,0.0003115247,0.004892438,0.0001533294,0.0001016777,0.008940737],"genre_scores_gemma":[0.9901409,0.0001218369,0.001296782,0.002998206,0.003689282,0.001048959,0.0001177862,0.00003995289,0.0005462826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01958525,"threshold_uncertainty_score":0.6770907,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2056641238","doi":"10.1182/blood-2012-10-460063","title":"MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":679,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Biology; Cancer research; Gene expression; Gene; Genetics; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.006845352635906837,"gpt":0.2294640225500546,"spread":0.2226186699141477,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002763383,0.0002745002,0.0005166254,0.00006277388,0.0001366451,0.00006800186,0.0002453627,0.0001801847,0.00005433223],"category_scores_gemma":[0.0004253738,0.0001421799,0.0001219001,0.0001647989,0.0001379455,0.00009578681,0.0002186007,0.0001358731,0.000009389967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000374775,"about_ca_system_score_gemma":0.000169356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001783791,"about_ca_topic_score_gemma":0.00006714857,"domain_scores_codex":[0.998068,0.000162424,0.0006003568,0.0004146423,0.0004726719,0.000281841],"domain_scores_gemma":[0.9977865,0.0005421713,0.0005579333,0.0005798787,0.000393545,0.0001399948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003784372,0.02340232,0.319835,0.00003632776,0.0002912041,0.0000457981,0.000199561,6.048053e-7,0.6538397,0.00001638099,0.0007632817,0.001191323],"study_design_scores_gemma":[0.02892641,0.0003175314,0.2751413,0.0002925795,0.0003004496,0.00001056596,0.0002079611,0.0000278216,0.6939664,0.00004772293,0.0006563097,0.0001049353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940375,0.001677879,0.0000274383,0.0007436604,0.0001342507,0.002876614,0.0003455346,0.00005388017,0.0001032135],"genre_scores_gemma":[0.9972544,0.0001879694,0.001344097,0.000102059,0.00008944783,0.0006919459,0.0002164557,0.00002804144,0.00008563248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04469372,"threshold_uncertainty_score":0.5797928,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2473498748","doi":"10.1200/jco.2016.67.3467","title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Brentuximab vedotin; Pembrolizumab; Internal medicine; Oncology; Cohort; Adverse effect; Lymphoma; Gastroenterology; Cancer; Immunotherapy; Hodgkin lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.03249842587650171,"gpt":0.355362388881699,"spread":0.3228639630051973,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006875096,0.0002732507,0.00165118,0.0001691797,0.00002568998,0.00001557599,0.0001525682,0.0004096658,0.0001178682],"category_scores_gemma":[0.0006090046,0.0001174291,0.0003269571,0.0001732888,0.0002884579,0.0001462642,0.00005081731,0.0003343986,0.00003284013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006384597,"about_ca_system_score_gemma":0.001842865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001450882,"about_ca_topic_score_gemma":0.0002074225,"domain_scores_codex":[0.9964498,0.0003352751,0.001728443,0.0003479066,0.000666781,0.0004717637],"domain_scores_gemma":[0.9964454,0.001145873,0.001087971,0.0002803225,0.0004471359,0.0005932893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03173611,0.01163342,0.707744,0.00001178743,0.0003671875,0.002107194,0.00002973581,3.596223e-7,0.000002632281,0.00003090934,0.0004819169,0.2458547],"study_design_scores_gemma":[0.1076406,0.03965305,0.820498,0.0004685295,0.0004497659,0.0003708941,0.00001710891,0.000002613274,0.00004660735,0.00004117181,0.03067207,0.0001395567],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850191,0.0001107002,0.0000370263,0.01372976,0.0002203692,0.0004745664,0.000005779007,0.00001397089,0.0003887495],"genre_scores_gemma":[0.9946709,0.00006641378,0.003719217,0.0008551301,0.0004672738,0.00005298854,0.000003313257,0.00003286781,0.000131901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2457152,"threshold_uncertainty_score":0.4788621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2057239580","doi":"10.1182/blood-2009-05-220095","title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":667,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"Diffuse large B-cell lymphoma; Hazard ratio; Vincristine; Internal medicine; Rituximab; Oncology; Medicine; Population; Cyclophosphamide; Lymphoma; CHOP; Chemotherapy; Confidence interval; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.007187967582575832,"gpt":0.2095229459765438,"spread":0.2023349783939679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000699271,0.0003460653,0.0005084453,0.0001473456,0.00007352413,0.00003380978,0.00008360087,0.0001256195,0.00002558116],"category_scores_gemma":[0.00002136921,0.0002274795,0.0000772325,0.0004869238,0.00002461958,0.00008003745,0.00001239361,0.00005958597,0.000017783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002439308,"about_ca_system_score_gemma":0.00006904811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008179563,"about_ca_topic_score_gemma":0.0001070562,"domain_scores_codex":[0.998247,0.00004793533,0.0002711753,0.0004701707,0.0004544572,0.0005093014],"domain_scores_gemma":[0.9991803,0.00002684198,0.0002008505,0.0002646123,0.0001432261,0.0001842035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007168523,0.1288361,0.8666357,0.00001608226,0.0003996575,0.0005307788,0.0002126763,1.149597e-7,0.0002795262,0.000001146342,0.0002109645,0.002160377],"study_design_scores_gemma":[0.1882808,0.003306497,0.7838655,0.0003577238,0.000456752,0.00001207636,0.00003627231,0.000007840178,0.02335518,0.000001595169,0.0001050978,0.0002146828],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969672,0.0002034223,6.240601e-7,0.0003538458,0.00001093606,0.00131682,0.0000707306,0.0001142487,0.0009621884],"genre_scores_gemma":[0.9978239,0.0001088539,0.0001989205,0.001003883,0.00002786334,0.0002079606,0.0002685863,0.00004982652,0.0003101846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1875639,"threshold_uncertainty_score":0.9276344,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2085346499","doi":"10.1182/blood-2013-11-531327","title":"Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":638,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Dalhousie University; University of Ottawa","funders":"National Cancer Institute; Teva Pharmaceutical Industries","keywords":"Bendamustine; Rituximab; Medicine; CHOP; Internal medicine; Oncology; Lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.03339717663584871,"gpt":0.3056359735912372,"spread":0.2722387969553885,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006192997,0.0002845795,0.00164438,0.0001362929,0.00005235566,0.00001002035,0.0001200952,0.0000817929,0.0002282544],"category_scores_gemma":[0.000507033,0.0001193385,0.0003250394,0.0002451378,0.0001142598,0.00002729086,0.00004037547,0.00005719174,0.0000104395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008311031,"about_ca_system_score_gemma":0.0001721062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001167251,"about_ca_topic_score_gemma":0.001216281,"domain_scores_codex":[0.9977539,0.0003157273,0.0009483516,0.0003236213,0.000407575,0.0002508443],"domain_scores_gemma":[0.9974532,0.001443978,0.0003145689,0.0006067184,0.0000887529,0.00009280299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8592901,0.1082013,0.01858292,0.00008890235,0.001445938,0.0001448589,0.002222738,0.000008490075,0.00003014655,0.00005420492,0.00007018659,0.009860264],"study_design_scores_gemma":[0.9631204,0.01436959,0.01202539,0.0001701507,0.002640802,0.00002781381,0.0001941792,0.00006049586,0.006355854,0.00002203467,0.0008985866,0.0001146877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926395,0.0004793827,0.000004994025,0.0007693775,0.0001673606,0.005441647,0.00002486653,0.0000223637,0.0004505157],"genre_scores_gemma":[0.9976661,0.0005511417,0.0001273287,0.00005485913,0.0002457296,0.0008995655,0.00001690924,0.00002395384,0.0004143857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1038304,"threshold_uncertainty_score":0.4866484,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045378618","doi":"10.1182/blood-2007-10-119974","title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":624,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Lymphoma; Immunology; Hodgkin lymphoma; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.006547399161925972,"gpt":0.2263341170731123,"spread":0.2197867179111863,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001692068,0.0001783012,0.0004983523,0.0001460193,0.0001320765,0.00001070083,0.00009141368,0.00006919276,0.00003935177],"category_scores_gemma":[0.00008448552,0.0001072067,0.0002468904,0.0004682519,0.0002615175,0.00003713195,0.00004860075,0.0000456995,0.00001068894],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003092692,"about_ca_system_score_gemma":0.0001260498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002228092,"about_ca_topic_score_gemma":0.0003390934,"domain_scores_codex":[0.9989161,0.00007271345,0.0003646591,0.0002600839,0.00021209,0.000174366],"domain_scores_gemma":[0.998998,0.000162637,0.0002319472,0.0004686661,0.00005757057,0.00008120587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001260822,0.001767862,0.9841176,0.00002067234,0.007545515,0.00005797077,0.001727415,0.00001111276,0.0002790899,0.00005736658,0.00005410596,0.00423521],"study_design_scores_gemma":[0.008457598,0.0004314826,0.9736021,0.00003900586,0.01218675,0.0001079702,0.000378312,0.0006003533,0.003952484,0.00003576493,0.00009898691,0.0001092082],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996012,0.002463018,0.00003762593,0.00024763,0.0000442598,0.0003073997,0.00002327065,0.00003093168,0.0008338696],"genre_scores_gemma":[0.9975353,0.001768544,0.0003246761,0.00008762526,0.00002075501,0.00004922825,0.00001844838,0.00001527888,0.0001801049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01051551,"threshold_uncertainty_score":0.4371762,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2923453543","doi":"10.1200/jco.18.02403","title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":616,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; Rituximab; Population; CHOP; Hazard ratio; Cyclophosphamide; Gastroenterology; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.03015399178565479,"gpt":0.3882991784214436,"spread":0.3581451866357888,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004221828,0.0003028114,0.00491922,0.0002164259,0.00003356191,0.00001538975,0.0001337159,0.000476534,0.0000924944],"category_scores_gemma":[0.001266513,0.0002017132,0.0006560002,0.0001309702,0.0003291288,0.000125512,0.0001298769,0.0004105036,0.00001251837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001893338,"about_ca_system_score_gemma":0.001014327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009312084,"about_ca_topic_score_gemma":0.00001995605,"domain_scores_codex":[0.994207,0.0006494886,0.003937433,0.0003789082,0.0004307862,0.0003964098],"domain_scores_gemma":[0.9917858,0.004674289,0.00253877,0.000271558,0.0002459055,0.0004836365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8507441,0.1054558,0.0255649,0.0001537392,0.0003019497,0.001112216,0.0002454925,4.276998e-7,0.0001593129,0.00003811615,0.0007288209,0.01549502],"study_design_scores_gemma":[0.9567341,0.01888002,0.01667021,0.0002416454,0.000936233,0.0003272273,0.0001270149,0.0004647571,0.0005363064,0.00005966,0.00486553,0.0001572777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914711,0.00197169,0.00002405538,0.0009888334,0.001039956,0.00151769,0.00002414865,0.000006271807,0.00295624],"genre_scores_gemma":[0.9924,0.004825103,0.001066521,0.0007958569,0.0004330933,0.00002223665,0.00001003549,0.00002454642,0.0004226132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.10599,"threshold_uncertainty_score":0.8225627,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152162065","doi":"10.1016/s1470-2045(15)00169-2","title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":613,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; H. Lundbeck A/S; University of British Columbia; Celgene; Terry Fox Research Institute; Genome British Columbia; Dr. Mildred Scheel Stiftung für Krebsforschung; Michael Smith Health Research BC; Amgen; Alfred Benzon Foundation; Genome Canada; Deutsche Krebshilfe","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Oncology; Population; Vincristine; Prednisone; International Prognostic Index; Cyclophosphamide; Lymphoma; Surgery; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.06967241767753558,"gpt":0.3970410134681473,"spread":0.3273685957906117,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001188848,0.00008568457,0.0006481889,0.0001824429,0.00003006636,0.000004771004,0.00004457736,0.0001113791,9.22583e-7],"category_scores_gemma":[0.003498874,0.00006149389,0.0001163247,0.0004533962,0.00005641935,0.00003736616,0.000006127255,0.00004316618,6.609819e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000583307,"about_ca_system_score_gemma":0.0001905223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006432296,"about_ca_topic_score_gemma":0.001356685,"domain_scores_codex":[0.9987875,0.0001865161,0.0006036807,0.0002106756,0.0001096529,0.0001020086],"domain_scores_gemma":[0.9976546,0.001161558,0.0005777135,0.0001969021,0.0003842138,0.00002503481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02096594,0.002214375,0.9666291,0.00002096135,0.0003464284,3.207836e-7,0.0008214616,0.0003086933,0.000035954,0.0001955942,0.000009953661,0.008451179],"study_design_scores_gemma":[0.09570821,0.003712841,0.8830721,0.00004609155,0.0008765151,3.225211e-7,0.0000842412,0.01441507,0.0006706993,0.001357782,0.00001134688,0.00004481753],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924354,0.00006913285,0.003359081,0.0005894536,0.00006087209,0.003365084,0.00009761544,0.000007040304,0.00001633028],"genre_scores_gemma":[0.9898498,0.000082238,0.008038856,0.00003107516,0.00007116512,0.001248667,0.0006683157,0.000007678799,0.000002205474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08355708,"threshold_uncertainty_score":0.4188732,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163401417","doi":"10.1038/nature09754","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","year":2011,"lang":"en","type":"article","venue":"Nature","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"CIITA; Biology; Cancer research; Lymphoma; Major histocompatibility complex; MHC class II; Fusion gene; MHC class I; Gene; Genetics; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.02121574103700218,"gpt":0.2779963934526211,"spread":0.2567806524156189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006653577,0.0001865439,0.0002730898,0.00009305775,0.00006222272,0.000005438139,0.00007676863,0.0006842657,0.000712676],"category_scores_gemma":[0.00001361885,0.0001343524,0.0001189748,0.0002176812,0.00002755093,0.00005752342,0.00002051411,0.0004883106,0.00002640828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000713726,"about_ca_system_score_gemma":0.0002411917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004364174,"about_ca_topic_score_gemma":0.0002065769,"domain_scores_codex":[0.9989218,0.00002240099,0.0001813709,0.0003357599,0.0002685019,0.0002701969],"domain_scores_gemma":[0.9994504,0.00001728361,0.00004984024,0.0002795828,0.00005185427,0.0001510505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005373924,0.008812851,0.4211093,0.0003340458,0.0009777095,0.001764892,0.0260179,0.00000451631,0.02006578,0.001116079,0.1661723,0.3482507],"study_design_scores_gemma":[0.01541915,0.001471131,0.5115322,0.0006063883,0.0003488227,0.0001582591,0.0002674772,0.0001545243,0.237895,0.0002041424,0.2314175,0.0005252802],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852452,0.006001381,0.000001961165,0.002073062,0.0004529339,0.0004041764,0.00004512623,0.00003806563,0.005738125],"genre_scores_gemma":[0.9951041,0.0009059661,0.0002628491,0.002957985,0.00009203733,0.00009186372,0.00003216683,0.00002035227,0.0005326631],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3477254,"threshold_uncertainty_score":0.7803303,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135321054","doi":"10.1200/jco.2007.13.5376","title":"Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; International Prognostic Index; Follicular lymphoma; Prednisone; Vincristine; Internal medicine; Subgroup analysis; Rituximab; Cyclophosphamide; Gastroenterology; Univariate analysis; Lymphoma; Surgery; Oncology; Confidence interval; Chemotherapy; Multivariate analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.03763512853676929,"gpt":0.3714512317465326,"spread":0.3338161032097633,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006929371,0.000241553,0.002506836,0.0001444904,0.00006249376,0.000003924237,0.000101392,0.0001589423,0.00001380509],"category_scores_gemma":[0.0004454304,0.0001397369,0.0001286611,0.000281021,0.0002575372,0.0001136497,0.00003915035,0.0002649885,0.000001078469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000233353,"about_ca_system_score_gemma":0.0008077032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003257256,"about_ca_topic_score_gemma":0.0002820059,"domain_scores_codex":[0.9963441,0.0003914073,0.002232664,0.0002690594,0.0005065888,0.0002561967],"domain_scores_gemma":[0.9960768,0.0008469189,0.001853702,0.0002601624,0.0005883839,0.0003739959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0676992,0.08403176,0.8187889,0.00002628458,0.0009175492,0.002885026,0.0006239692,0.00004442911,0.000007044646,0.000001815667,0.0001064177,0.02486763],"study_design_scores_gemma":[0.2690184,0.1119683,0.6173728,0.0001957497,0.0006111519,0.0002428245,0.0002315283,0.00001926232,0.00004631892,0.000002965957,0.0002075742,0.00008306626],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979067,0.0005301855,0.000009524658,0.0001628614,0.00008982979,0.00113162,0.000005414673,0.000009216287,0.0001546312],"genre_scores_gemma":[0.9975442,0.0003846545,0.001752411,0.0001751027,0.0000562706,0.00002320714,0.0000107793,0.0000219526,0.00003140319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2014161,"threshold_uncertainty_score":0.5698304,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3092484545","doi":"10.1016/s1470-2045(20)30441-1","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cilag; Takeda Pharmaceutical Company; AbbVie; National Cancer Institute; Merck Sharp and Dohme; Pharmacyclics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Roche","keywords":"Open label; Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Follicular phase; Clinical trial; Lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.1386246272526778,"gpt":0.3873040580453387,"spread":0.2486794307926609,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002526804,0.0002489486,0.0008928779,0.00002964557,0.0001665143,0.000046346,0.0003527804,0.000136235,0.0001178821],"category_scores_gemma":[0.000393605,0.0001277683,0.00005140621,0.0001720813,0.0001027417,0.0001502359,0.0001088024,0.00008927446,0.00003559585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004287475,"about_ca_system_score_gemma":0.0004133528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005203185,"about_ca_topic_score_gemma":0.00007259683,"domain_scores_codex":[0.9982566,0.0002445173,0.0003529645,0.0004595875,0.0002343932,0.0004518958],"domain_scores_gemma":[0.9982622,0.0005416351,0.0002576578,0.0004977779,0.0001572827,0.0002834361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7688298,0.0732818,0.001767502,0.00008116858,0.0007461093,0.000481308,0.001466051,0.000002227927,0.0005082683,0.0002807181,0.02081438,0.1317407],"study_design_scores_gemma":[0.5880129,0.1284346,0.0008670066,0.00003154034,0.0006231972,0.00001295313,0.0001380537,0.0001604064,0.0003567439,0.00002428254,0.2811848,0.0001534461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840698,0.0001470744,0.00004348892,0.009165845,0.0003369846,0.004950367,0.0001432622,0.00008547128,0.001057712],"genre_scores_gemma":[0.981441,0.00008507988,0.005595835,0.01046238,0.0009598135,0.0007688676,0.000463335,0.0000554604,0.0001681871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2603704,"threshold_uncertainty_score":0.5210239,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153944703","doi":"10.1182/blood-2009-03-212191","title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":584,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; Terry Fox Foundation; National Institutes of Health; Michael Smith Health Research BC","keywords":"Chromosomal translocation; Follicular lymphoma; Lymphoma; International Prognostic Index; Fluorescence in situ hybridization; Rituximab; Internal medicine; Aggressive lymphoma; Diffuse large B-cell lymphoma; Oncology; Biology; Cytogenetics; Chemotherapy; Gene rearrangement; Medicine; Cancer research; Gene; Chromosome; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02694694733325743,"gpt":0.2697737939056961,"spread":0.2428268465724386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006420145,0.0001453342,0.0002117457,0.00002343608,0.0001225682,0.00003237681,0.0000378697,0.00004460486,0.00002181849],"category_scores_gemma":[0.0000570537,0.00006854125,0.00003373045,0.0001211723,0.0001270051,0.00004091073,0.000003924863,0.00005331178,0.000002313643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003879642,"about_ca_system_score_gemma":0.0001064926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002967967,"about_ca_topic_score_gemma":0.0000452606,"domain_scores_codex":[0.9992256,0.00003919038,0.0001145942,0.0001881341,0.0002427282,0.0001897427],"domain_scores_gemma":[0.9993524,0.0002664241,0.00002742487,0.0001555611,0.00007826558,0.000119944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001189673,0.008538183,0.9719183,0.00002807437,0.0008821105,0.0001661469,0.001582456,0.000001225141,0.0001490055,0.00895712,0.000203726,0.007454622],"study_design_scores_gemma":[0.009214694,0.001544193,0.9848012,0.0001577983,0.001111599,0.00005617689,0.0003054695,0.00001048049,0.002330434,0.00005577836,0.0002947481,0.0001174058],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931197,0.001114895,0.00002590497,0.004151036,0.00003032274,0.0003000917,0.00002032704,0.00005120586,0.001186557],"genre_scores_gemma":[0.9995058,0.00005110072,0.00003994536,0.0002518415,0.00004035467,0.00002625581,0.00003732414,0.000009874858,0.00003752864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01288286,"threshold_uncertainty_score":0.2795031,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2020789296","doi":"10.1182/blood-2014-05-577189","title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","year":2014,"lang":"en","type":"review","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; Context (archaeology); Lymphoma; Medicine; Ibrutinib; Cancer research; Internal medicine; Biology; Leukemia; Chronic lymphocytic leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.1056111912434274,"gpt":0.3951667525710021,"spread":0.2895555613275748,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001003276,0.0003372923,0.002810937,0.00008020472,0.00003514767,0.00001434892,0.0001803053,0.0003713658,0.00000497496],"category_scores_gemma":[0.0002051454,0.0001640371,0.0007115356,0.0001066946,0.0001104523,0.00001410144,0.0001133465,0.0001508205,0.00002126224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002302063,"about_ca_system_score_gemma":0.0001015787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003287754,"about_ca_topic_score_gemma":0.00001770416,"domain_scores_codex":[0.9974511,0.0004762177,0.001240912,0.0004181664,0.0001556937,0.0002578866],"domain_scores_gemma":[0.997907,0.0009322875,0.0004687502,0.0005692647,0.00002579554,0.00009694772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002865427,0.04205003,0.3261175,0.01221092,0.000709403,0.0003477976,0.00009559177,6.146742e-9,2.147293e-7,0.0002074298,0.00009607309,0.6181363],"study_design_scores_gemma":[0.07196796,0.001264334,0.02315938,0.006363182,0.008479162,0.0004231962,0.00009510553,0.000003360059,0.00002059624,0.000007079179,0.8877751,0.000441539],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1110181,0.8876392,9.354917e-7,0.00003316933,0.00008816643,0.0008429079,0.00006055397,0.00001298467,0.0003039754],"genre_scores_gemma":[0.1511137,0.8481392,0.0001427141,0.0002994765,0.0001007462,0.0001076574,0.00006174094,0.00001971169,0.00001501244],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.887679,"threshold_uncertainty_score":0.6689237,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2016783244","doi":"10.1182/blood-2013-11-536359","title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":540,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; China Scholarship Council; Center for Clinical and Translational Research; University of Nebraska Medical Center; Lymphoma Research Foundation","keywords":"Lymphoma; Gene expression; Peripheral T-cell lymphoma; Biology; Gene expression profiling; Cancer research; Medicine; Gene; Pathology; Immunology; T cell; Genetics; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01183315777556138,"gpt":0.2298798830586328,"spread":0.2180467252830714,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009276978,0.0001489999,0.000237679,0.00004659143,0.00004034059,0.0000172662,0.00004048975,0.0001255168,0.00003633302],"category_scores_gemma":[0.00007455101,0.00009532989,0.00004602126,0.00006542591,0.00004026638,0.00002646148,0.00004290147,0.00004451887,0.00001146356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002532413,"about_ca_system_score_gemma":0.00002290186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002188981,"about_ca_topic_score_gemma":0.000005971361,"domain_scores_codex":[0.9991601,0.00005737858,0.0001721499,0.0002878674,0.0001092431,0.0002132488],"domain_scores_gemma":[0.9995778,0.00009322363,0.00003604559,0.0001500913,0.00002465709,0.000118191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001037786,0.00344105,0.9064849,0.00002903974,0.00002100211,0.000194851,0.000102745,0.000002873216,0.08140387,0.00002002573,0.0000572115,0.008138667],"study_design_scores_gemma":[0.01482138,0.0008623375,0.7652693,0.0000993315,0.00008874173,0.00008823538,0.00002417793,0.000189309,0.2178808,0.00006401088,0.0004713977,0.0001409443],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959567,0.003013402,0.00001937734,0.0001330115,0.00003670892,0.0002881936,0.000003630526,0.00003093654,0.0005179977],"genre_scores_gemma":[0.9970676,0.0002554744,0.002180965,0.0002185464,0.0001219323,0.00006583029,0.00003613515,0.0000117233,0.00004180389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1412155,"threshold_uncertainty_score":0.388744,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1972168709","doi":"10.1182/blood-2002-01-0099","title":"The role of cytokines in classical Hodgkin lymphoma","year":2002,"lang":"en","type":"review","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Cytokine; Chemokine; Immune system; Biology; Immunology; Tumor necrosis factor alpha; Cancer research; Lymphoma; T cell; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02666551994444972,"gpt":0.2915230698729212,"spread":0.2648575499284715,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009994322,0.0002754635,0.00132756,0.0000990328,0.00003494672,0.00001406915,0.0001497664,0.0002228219,0.00003345474],"category_scores_gemma":[0.00007238481,0.0001418405,0.0004747736,0.0002448086,0.00007252401,0.00001328727,0.00005613177,0.00008443073,0.00008598027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001021296,"about_ca_system_score_gemma":0.0001935065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000347234,"about_ca_topic_score_gemma":0.00001945247,"domain_scores_codex":[0.9986405,0.00008421725,0.0005350495,0.0002590718,0.0002400948,0.0002410903],"domain_scores_gemma":[0.9988698,0.0003515268,0.0002003678,0.0004718049,0.00002881886,0.00007769111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005427592,0.002240687,0.001100486,0.001274509,0.000324835,0.000142823,0.00001564222,6.114049e-9,3.245488e-7,0.0004502227,0.0002380185,0.994207],"study_design_scores_gemma":[0.00246894,0.0001790221,0.001059863,0.00642325,0.002094405,0.0002387671,0.000009779646,0.000001238474,0.00004557049,0.00003857444,0.9873235,0.0001171011],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005327842,0.9919583,3.204543e-8,0.00006767978,0.00005975159,0.0005942652,0.00002247832,0.00001690343,0.006747838],"genre_scores_gemma":[0.00135416,0.9977258,0.00004052818,0.00001421881,0.0001779151,0.0002480244,0.00002744185,0.00003232409,0.000379573],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9940899,"threshold_uncertainty_score":0.5784089,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074678620","doi":"10.1182/blood-2012-02-408542","title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Fondation pour la Recherche Médicale","keywords":"Angioimmunoblastic T-cell lymphoma; Lymphoma; Peripheral T-cell lymphoma; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Not Otherwise Specified; T cell; Gastroenterology; Oncology; Cancer research; Immunology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01871058031353838,"gpt":0.2828336209555949,"spread":0.2641230406420565,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001291155,0.0001613183,0.000273977,0.00005880009,0.00004810617,0.00001191263,0.0000319349,0.00009464801,0.00002967898],"category_scores_gemma":[0.0000330564,0.0001119271,0.00007491191,0.0001091835,0.0001000867,0.00008418214,0.00002299579,0.0001137034,0.00002259517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006290609,"about_ca_system_score_gemma":0.00008281811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000873754,"about_ca_topic_score_gemma":0.00005802362,"domain_scores_codex":[0.9990361,0.00005941769,0.0002411904,0.0002310659,0.0001508531,0.0002814193],"domain_scores_gemma":[0.9993293,0.000137884,0.00007026024,0.0001890343,0.00002463075,0.0002489426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002035811,0.004857546,0.9872574,0.00002560779,0.0001336213,0.0001481769,0.0007137806,0.000003132531,0.00002037616,0.00004037963,0.0002376321,0.006358766],"study_design_scores_gemma":[0.01714163,0.0008631754,0.9788474,0.0001134857,0.0006028719,0.0003397428,0.0003536308,0.00001879397,0.0004316397,0.00001106491,0.001131401,0.0001451596],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936541,0.003543326,0.000002126241,0.0001905471,0.0002281812,0.0003631661,0.000009184864,0.00003044419,0.001978865],"genre_scores_gemma":[0.9967986,0.0003437605,0.002147501,0.0002212797,0.00006749977,0.00007171235,0.00003758748,0.00001744095,0.0002945932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01693805,"threshold_uncertainty_score":0.4564254,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140485109","doi":"10.1200/jco.2010.30.0368","title":"Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Concordance; Medicine; Tissue microarray; Diffuse large B-cell lymphoma; Rituximab; Microarray; Lymphoma; CHOP; Vincristine; Oncology; International Prognostic Index; Internal medicine; Hazard ratio; Immunohistochemistry; Algorithm; Cyclophosphamide; Chemotherapy; Biology; Confidence interval; Computer science; Gene; Gene expression; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03512157496791447,"gpt":0.4173512255464819,"spread":0.3822296505785674,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00180493,0.000169381,0.001560827,0.0001048563,0.0000290769,0.000005514094,0.00009216863,0.0003219435,0.00001243467],"category_scores_gemma":[0.0007860864,0.00009652405,0.0001843707,0.0001071176,0.0001835461,0.00006867047,0.00003247373,0.0003695992,5.353509e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000126604,"about_ca_system_score_gemma":0.0006967043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004112687,"about_ca_topic_score_gemma":0.00003612886,"domain_scores_codex":[0.9976696,0.0002291132,0.001423561,0.0002120711,0.0002208132,0.0002448676],"domain_scores_gemma":[0.9948338,0.003052088,0.00125934,0.0001791194,0.0004179322,0.000257692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01462419,0.04358098,0.9126264,0.00005662859,0.0001934963,0.00007192694,0.00007064854,1.948617e-7,0.000644183,0.00001951745,0.00004645924,0.02806537],"study_design_scores_gemma":[0.2186357,0.02148639,0.7536017,0.0000910657,0.0006109768,0.00004333044,0.00005014332,0.00008536479,0.002297816,0.00001744541,0.002987305,0.00009281065],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982488,0.000159196,0.0001863211,0.0002057814,0.000253183,0.0004020093,0.00001306618,0.000005358289,0.0005263519],"genre_scores_gemma":[0.9513307,0.00006154031,0.04828374,0.0001091891,0.0001334484,0.0000135223,0.000009228756,0.00002051076,0.00003817499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2040115,"threshold_uncertainty_score":0.3936136,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043622833","doi":"10.1182/blood-2014-05-578963","title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":466,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Transplantation; BCL6; Retrospective cohort study; Autologous stem-cell transplantation; Regimen; Leukocytosis; Oncology; Surgery; Immunology; B cell","retraction":null,"screen_n_in":null,"score":{"opus":0.01142777403654259,"gpt":0.266469929878576,"spread":0.2550421558420334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008338034,0.000114079,0.0003563701,0.0002417646,0.0000179311,0.000007956558,0.0000202406,0.00005923682,0.000009713451],"category_scores_gemma":[0.000003569072,0.00007923047,0.0001408486,0.0002274594,0.00001731978,0.00004769241,0.000004651426,0.00002860773,0.000003165278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000136088,"about_ca_system_score_gemma":0.00001982064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006962503,"about_ca_topic_score_gemma":0.00009306048,"domain_scores_codex":[0.9993216,0.000033136,0.0001851284,0.0002039581,0.000146746,0.0001093973],"domain_scores_gemma":[0.9996145,0.00004571073,0.00009374366,0.000156695,0.00003473965,0.00005455174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004019311,0.002824633,0.9930818,0.0000330149,0.0008556633,0.00001541093,0.0008920762,0.00001544575,0.0004784752,0.00004043029,0.000002867696,0.001358249],"study_design_scores_gemma":[0.02387754,0.0008555186,0.958932,0.00003944539,0.002025058,0.000006236394,0.00005411042,0.00007231206,0.01406738,0.000006216302,0.000001368079,0.00006283278],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986082,0.00003872975,0.000009253872,0.00005884767,0.00001762525,0.0002576061,0.00001274857,0.0000120568,0.0009849037],"genre_scores_gemma":[0.9996985,0.00006930498,0.00006436532,0.00001622574,0.00001524591,0.00002421629,0.00002440398,0.000007619201,0.00008015931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03414983,"threshold_uncertainty_score":0.3230925,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133345449","doi":"10.1200/jco.2013.53.9593","title":"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Eli Lilly Canada; Eli Lilly and Company","keywords":"Medicine; Gemcitabine; DHAP; Autologous stem-cell transplantation; Internal medicine; Oncology; Cytarabine; Transplantation; Aggressive lymphoma; Population; Chemotherapy; Gastroenterology; Rituximab; Urology; Surgery; Lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.0665883136468229,"gpt":0.4124516741035159,"spread":0.345863360456693,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004153774,0.0003474593,0.003839927,0.0002120428,0.00009229172,0.00001933519,0.0001060671,0.0006836354,0.00001884504],"category_scores_gemma":[0.00289713,0.0002398314,0.0004557373,0.0001010212,0.0006532738,0.0001531821,0.00002764306,0.0004250106,8.927599e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001314592,"about_ca_system_score_gemma":0.0005035444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004725407,"about_ca_topic_score_gemma":0.00008558061,"domain_scores_codex":[0.9949983,0.0009838927,0.002916151,0.0004172372,0.0003727284,0.0003117217],"domain_scores_gemma":[0.9735608,0.02107942,0.004323524,0.0002179111,0.0003922624,0.0004260799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3628067,0.002195017,0.1089663,0.000395673,0.00111897,0.0001157897,0.001388326,0.00001133294,0.0003977963,0.0003423328,0.0003802303,0.5218815],"study_design_scores_gemma":[0.6267493,0.02996931,0.3319714,0.0004195906,0.003144148,0.0004308845,0.0003357222,0.003325854,0.001045055,0.0004729854,0.001899241,0.0002365637],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990829,0.004223226,0.001236833,0.001495876,0.0005928399,0.001044892,0.00002066789,0.00001478842,0.0005418573],"genre_scores_gemma":[0.9718104,0.005942238,0.02140372,0.0003993904,0.0002797713,0.00004169598,0.00001786586,0.00003639172,0.00006855038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5216449,"threshold_uncertainty_score":0.9780039,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2190884983","doi":"10.1016/s0140-6736(15)00667-4","title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Temsirolimus; Refractory (planetary science); Open label; Medicine; Oncology; Lymphoma; Phases of clinical research; Internal medicine; Clinical trial; Discovery and development of mTOR inhibitors; Materials science; Leukemia; Biology; Chronic lymphocytic leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.1087202323479117,"gpt":0.3677079421229318,"spread":0.2589877097750201,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004613233,0.0001918782,0.0005292083,0.00006394907,0.0000568517,0.00007221102,0.000460448,0.00004558612,0.0000596032],"category_scores_gemma":[0.0001214386,0.00009719076,0.00001950487,0.0001483979,0.00004579684,0.0002325831,0.0001201875,0.0000807633,0.00005928965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003171507,"about_ca_system_score_gemma":0.0001950382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003601659,"about_ca_topic_score_gemma":0.0001473092,"domain_scores_codex":[0.9985834,0.0001557973,0.0002738079,0.0003131357,0.0004196498,0.0002542096],"domain_scores_gemma":[0.9986978,0.0001664131,0.0001419354,0.0007268633,0.0001099607,0.0001570695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5030558,0.06402034,0.4100783,0.0000139502,0.0003906427,0.0004260359,0.002170752,0.000004156007,0.00001055429,0.00002688716,0.009333771,0.01046889],"study_design_scores_gemma":[0.8329839,0.0117766,0.1449697,0.00005340604,0.0001809141,0.000005075163,0.0006656828,0.00005956824,0.00005642828,0.00000665063,0.009101759,0.0001402874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882004,0.00008162981,5.735242e-7,0.0004637164,0.0003878426,0.002045567,0.00003818142,0.00003923854,0.008742902],"genre_scores_gemma":[0.9982272,0.00004366714,0.0001722604,0.0004332582,0.0002545848,0.0002370935,0.0001282415,0.00002754708,0.0004761382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3299282,"threshold_uncertainty_score":0.3963324,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1969267175","doi":"10.1182/blood-2005-04-1565","title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":456,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; International Prognostic Index; Follicular lymphoma; Internal medicine; Gastroenterology; CD68; Lymphoma; Vincristine; Rituximab; Prednisone; Chemotherapy; Cyclophosphamide; Oncology; Immunohistochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.03216766737090314,"gpt":0.2545637908689651,"spread":0.2223961234980619,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004512601,0.000342575,0.001261848,0.0006042096,0.00004377951,0.00001731427,0.0002041838,0.0002545027,0.0002541402],"category_scores_gemma":[0.0001267799,0.0002870092,0.0006347357,0.0009303023,0.000100028,0.0001264941,0.00008090529,0.00004156708,0.000005948049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004235998,"about_ca_system_score_gemma":0.0001846082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00327397,"about_ca_topic_score_gemma":0.003802782,"domain_scores_codex":[0.9971458,0.0001675943,0.0008254724,0.0005552114,0.0008642283,0.0004417329],"domain_scores_gemma":[0.9982663,0.00016626,0.0004296051,0.0006738612,0.0001932973,0.0002706294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003590626,0.01628758,0.9557931,0.00004379789,0.01072586,0.000220437,0.0009121864,0.00002483602,0.008163022,0.00001401503,0.00002539469,0.007430641],"study_design_scores_gemma":[0.03149083,0.0004598705,0.8497527,0.00009894903,0.005617246,0.00001029321,0.0005096168,0.001913879,0.1098694,0.000001939109,0.00008119495,0.0001940973],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996854,0.001418079,0.000007142,0.0001292016,0.00007923628,0.0006547627,0.0005081397,0.00004515965,0.0003042714],"genre_scores_gemma":[0.998873,0.0001874803,0.0002173795,0.0001310758,0.00003558405,0.00007690178,0.0003000303,0.00003615894,0.000142404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1060405,"threshold_uncertainty_score":0.9999582,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2100367991","doi":"10.1200/jco.2003.11.141","title":"Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; International Prognostic Index; Radiation therapy; Chemotherapy; Anthracycline; Stage (stratigraphy); Lymphoma; Internal medicine; Surgery; Retrospective cohort study; Diffuse large B-cell lymphoma; Cancer; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1053388082581795,"gpt":0.3874672162959088,"spread":0.2821284080377293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002917823,0.000143988,0.001125008,0.0001071646,0.00001957481,0.0000067583,0.0002842243,0.0001646913,0.00005383792],"category_scores_gemma":[0.002575416,0.00007078661,0.000234771,0.0001585035,0.0001184241,0.00006306038,0.0001172127,0.0002088284,9.005107e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002657151,"about_ca_system_score_gemma":0.0002301442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006761654,"about_ca_topic_score_gemma":0.00179128,"domain_scores_codex":[0.9960257,0.0008116939,0.002338967,0.000172689,0.0004725219,0.0001784586],"domain_scores_gemma":[0.992127,0.006129446,0.001304907,0.0001873071,0.0001473346,0.0001039755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005103436,0.0322343,0.9465383,0.00002263942,0.0001649926,0.0001896812,0.0003655509,9.157408e-7,0.00002269974,0.000004703435,0.0002478154,0.01969801],"study_design_scores_gemma":[0.03057771,0.0049198,0.9633735,0.0000948428,0.0001509682,0.00008925051,0.0002923069,0.00004614818,0.00003038056,0.000009193139,0.0003609173,0.00005495587],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970652,0.0004734412,0.000003477628,0.001280443,0.000451503,0.0004558104,0.00004419273,0.000001772684,0.0002241651],"genre_scores_gemma":[0.9990823,0.0002802383,0.00004111783,0.0004540508,0.00005966342,0.000009130527,0.000004100519,0.00001044205,0.00005897195],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03006736,"threshold_uncertainty_score":0.3083199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1983084203","doi":"10.1182/blood-2010-09-310342","title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":429,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Peripheral T-cell lymphoma; Lymphoma; Internal medicine; International Prognostic Index; Anthracycline; Not Otherwise Specified; B symptoms; Stage (stratigraphy); T-cell lymphoma; Multivariate analysis; Oncology; Chemotherapy; Disease; Survival analysis; Gastroenterology; Cancer; Diffuse large B-cell lymphoma; T cell; Immunology; Breast cancer; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.04157237539381178,"gpt":0.2569832007150762,"spread":0.2154108253212644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001644315,0.0003466481,0.0004766325,0.0000693034,0.00009863408,0.00004504446,0.0003314961,0.0001315725,0.001147845],"category_scores_gemma":[0.00006897085,0.0002286333,0.0003515253,0.0001518304,0.0001493562,0.0001008698,0.0001169497,0.00005642678,0.00005072349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002237492,"about_ca_system_score_gemma":0.0005277311,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008273018,"about_ca_topic_score_gemma":0.0003051495,"domain_scores_codex":[0.9978575,0.0000619811,0.0006065071,0.0005511022,0.0005856825,0.0003372963],"domain_scores_gemma":[0.9984116,0.0001431617,0.0003413876,0.0008141621,0.0001603297,0.0001293369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00336242,0.05878647,0.8460966,0.000135727,0.002223351,0.02416575,0.01299072,0.000001296424,0.02261395,0.0002702646,0.01274733,0.0166061],"study_design_scores_gemma":[0.04885441,0.001453843,0.4792354,0.0001990218,0.001404218,0.004528923,0.002386048,0.00005695318,0.4227408,0.00006287587,0.03848598,0.0005915052],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.949072,0.001058891,0.000006650037,0.0002726199,0.0004235076,0.0006373713,0.0001584063,0.00006941755,0.04830113],"genre_scores_gemma":[0.9930341,0.0002005944,0.002172321,0.0005790586,0.0005637767,0.0001493264,0.0001224139,0.00005774071,0.003120702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4001269,"threshold_uncertainty_score":0.9997652,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171873783","doi":"10.1200/jco.2012.44.7524","title":"Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surrey Memorial Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Disease; Lymphoma; Oncology; Peripheral; Internal medicine; Peripheral T-cell lymphoma; T cell; Immunology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.02960347864657775,"gpt":0.35222057892783,"spread":0.3226171002812522,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004407682,0.0001784689,0.001363679,0.00007283003,0.00002725439,0.00000846386,0.00009897753,0.0001876789,0.000581934],"category_scores_gemma":[0.0003949836,0.00009063334,0.0002832196,0.00009448917,0.0003415908,0.000136,0.00006660569,0.0001562513,0.000004433263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001093762,"about_ca_system_score_gemma":0.0008478273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003255757,"about_ca_topic_score_gemma":0.0002018022,"domain_scores_codex":[0.9973493,0.0002193914,0.001573963,0.0001986736,0.0004528917,0.0002058312],"domain_scores_gemma":[0.9963887,0.0009150293,0.001465761,0.0002232335,0.0004170682,0.0005901916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02492277,0.01147013,0.9409035,0.0001960744,0.0002816871,0.0008499911,0.00008210332,7.558859e-7,0.000001218096,0.000003842219,0.0002474085,0.02104046],"study_design_scores_gemma":[0.02590406,0.02196997,0.9504644,0.0004290279,0.0005573226,0.00003434844,0.00003551358,0.000006376046,0.00003884323,0.00001866223,0.0004509374,0.00009048995],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963937,0.0006386572,0.000004071785,0.001859059,0.0004450067,0.0004542893,0.0000145791,0.000003972998,0.0001866429],"genre_scores_gemma":[0.9982713,0.0005587531,0.0005489134,0.0001816688,0.0002327962,0.00001933848,0.000006636226,0.0000185492,0.0001620119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02094997,"threshold_uncertainty_score":0.6371769,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}